参考文献/References:
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. [2]Benjamin EJ,Blaha MJ,Chiuve SE,et al.Heart Disease and Stroke Statistics-2017 Update:A Report From the American Heart Association[J].Circulation,2017,135(10):e196. [3]Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of CardiologyAmerican Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].J Am Coll Cardiol,2017,70(6):776-803. [4]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789. [5]Tanai E,Frantz S.Pathophysiology of Heart Failure[J].Compr Physiol,2015,6(1):187-214. [6]Mollace V,Gliozzi M,Capuano A,et al.Modulation of RAAS-natriuretic peptides in the treatment of HF:Old guys and newcomers[J].Int J Cardiol,2017(226):126-131. [7]Ghazi L,Drawz P.Advances in understanding the renin-angiotensin-aldosterone system(RAAS)in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy[J].F1000Res,2017(6):F1000. [8]Polhemus DJ,Trivedi RK,Gao J,et al.Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney[J].J Am Coll Cardiol,2017,70(17):2139-2153. [9]Bayes-Genis A,Barallat J,Galan A,et al.Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients[J].J Am Coll Cardiol,2015,65(7):657-665. [10]Senni M,McMurray JJ,Wachter R,et al.Initiating sacubitril/valsartan(LCZ696)in heart failure: results of TITRATION,a double-blind,randomized comparison of two uptitration regimens[J].Eur J Heart Fail,2016,18(9):1193-1202. [11]Solomon SD,Zile M,Pieske B,et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J].The Lancet,2012,380(9851):1387-1395. [12]McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004. [13]崔晓通,周京敏,葛均波.PARADIGM-HF研究结果解读[J].中国循环杂志,2018,33(2):203-205. [14]Yancy CW,Jessup M,Bozkurt B,et al.2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure:An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of CardiologyAmerican Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].J Am Coll Cardiol,2016,68(13):1476-1488. [15]Pascual-Figal D,Wachter R,Senni M,et al.Rationale and design of TRANSITION:a randomized trial of pre-discharge vs.post-discharge initiation of sacubitril/valsartan[J].ESC Heart Fail,2018,5(2):327-336. [16]Velazquez EJ,Morrow DA,DeVore AD,et al.Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure[J].N Engl J Med,2019,380(6):539-548. [17]Mogensen UM,K?ber L,Kristensen SL,et al.The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF[J].Am Heart J,2017(188):35-41. [18]Bohm M,Young R,Jhund PS,et al.Systolic blood pressure,cardiovascular outcomes and efficacy and safety of sacubitril/valsartan(LCZ696)in patients with chronic heart failure and reduced ejection fraction:results from PARADIGM-HF[J].Eur Heart J,2017,38(15):1132-1143. [19]Jhund PS,Fu M,Bayram E,et al.Efficacy and safety of LCZ696(sacubitril-valsartan)according to age:insights from PARADIGM-HF[J].European Heart Journal,2015,36(38):2576-2584. [20]Desai AS,Vardeny O,Claggett B,et al.Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril:A Secondary Analysis of the PARADIGM-HF Trial[J].JAMA Cardiol,2017,2(1):79-85. [21]Tyler JM,Teerlink JR.The safety of sacubitril-valsartan for the treatment of chronic heart failure[J].Expert Opinion on Drug Safety,2017,16(2):257. [22]Han Y,Ayalasomayajula S,Pan W,et al.Pharmacokinetics,Safety and Tolerability of Sacubitril/Valsartan(LCZ696)After Single-Dose Administration in Healthy Chinese Subjects[J].Eur J Drug Metab Pharmacokinet,2017,42(1):109-116.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(02):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(02):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(02):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]平兰芝,黄小楼,胡天俊,等.CaMKⅡ在心血管疾病中的研究[J].医学信息,2022,35(10):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
PING Lan-zhi,HUANG Xiao-lou,HU Tian-jun,et al.Research on the Role of CaMKⅡ in Cardiovascular Diseases[J].Medical Information,2022,35(02):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
[6]刘革铭,马洪俊,刘 毅,等.心力衰竭的机制及诊疗的研究[J].医学信息,2022,35(10):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
LIU Ge-ming,MA Hong-jun,LIU Yi,et al.Mechanism, Diagnosis and Treatment of Heart Failure[J].Medical Information,2022,35(02):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
[7]黄光明,赵兴昌,符显昭.水中运动联合中药内治对糖尿病大鼠心肌细胞凋亡和心功能的影响[J].医学信息,2022,35(11):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
HUANG Guang-ming,ZHAO Xing-chang,FU Xian-zhao.Effects of Aquatic Therapeutic Exercise Combined with Traditional Chinese Medicine Internal Treatment on Cardiomyocyte Apoptosis and Cardiac Function in Diabetic Rats[J].Medical Information,2022,35(02):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
[8]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(02):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[9]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(02):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[10]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(02):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[11]韦怡春,易秋艳.沙库巴曲缬沙坦对心力衰竭患者抑郁的影响[J].医学信息,2021,34(23):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
WEI Yi-chun,YI Qiu-yan.Effect of Sacubitril Valsartan on Depression in Patients with Heart Failure[J].Medical Information,2021,34(02):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]